IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA

Immunol Allergy Clin N Am
23 (2003) 815–836

Cumulative Index 2003

Volume 23

February	IMPACT OF IMMUNE SENESCENCE ON HUMAN AGING, pages 1–154
May	OCCUPATIONAL ASTHMA AND ALLERGY, pages 155–336
August	AEROBIOLOGY, pages 337–554
November	VACCINES IN THE 21ST CENTURY, pages 555–836

Note: Page numbers of article titles are in **boldface** type.

A

Acari. *See* Mites; Dust mites.

Acid anhydrides, occupational asthma from, 225

Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection.

Activator protein-1, in elderly persons, tumor susceptibility and, 98–99

Activities of daily living, dependency in, in elderly persons, infections and, 61

Acute disseminated encephalomyelitis, from Japanese encephalitis vaccine, 685–689

Acute-phase response, cytokines in, in elderly persons, 16–18

Adaptation, to synthetic chemicals, failure of, environmental sensitivity in, 313

Adjuvants, for transcutaneous immunization, 791–792
  clinical studies of, 802–805
  in immunostimulant patch, 795–800
  mucosal response to, 801–802
  safety of, 792–795
  systemic immune response to, 800–801

Aeroallergens, floristic zones and. *See* Floristic zones.

Aerosol challenge test, in occupational asthma, 245, 262–263

Aging. *See* Elderly persons.

AIDS. *See* Human immunodeficiency virus infection.

Air cleaners, for allergen control, 477–478

Air-O-Cell sampler, for bioaerosols, 345

Air sampling
  for biological particles, **337–355**
    analytical techniques used after, 338–341
    animal allergens, 472–474
    devices for
      centrifugal impactors, 348–349
      filtration samplers, 350–351
      inertial impactors, 341, 343
      liquid impingers, 349–350
      list of, 342
      rotating-arm impactors, 347–348
      spore traps, 526
      suction sieve-plate samplers, 345–347
      suction slit impactors, 343–345
    fungal allergens, 293–294, 509–511, 526–528
    indoor, 338, 526–528
    isoaxial, 338
    isokinetic, 338
    mountain cedar pollen, 431–439
    outdoor, 338
    reasons for, 337
  in toxic exposures, 181–182

Airport MD8 sampler, for bioaerosols, 351

Airway hyperreactivity, in occupational asthma, 237

Albumin, in vaccines, allergy to, 578

0889-8561/03/$ – see front matter © 2003 Elsevier Inc. All rights reserved.
doi:10.1016/S0889-8561(03)00126-7

Allergenco MK-3 sampler, for bioaerosols, 344–345

Allergic contact dermatitis, occupational
  antigens causing, 281–284
  diagnosis of, 274–276, 279–281
  epidemiology of, 269–271
  from fungi, 304
  from latex exposure, 210
  pathophysiology of, 271–273
  physical examination in, 277–279
  risk factors for, 273–274
  versus irritant contact dermatitis, 285

Allergic fungal sinusitis, 299

Allergic theory, of environmental sensitivity, 314

Allergic toxemia theory, of environmental sensitivity, 313–314

Allergy
  egg. *See* Egg allergy.
  fungi, 297–300, 304, 321
  latex. *See* Latex allergy.
  universal. *See* Environmental sensitivity.
  vaccine. *See* Vaccine(s), allergy to.

Alternaria, allergens of, 298

Aluminum, in vaccines, allergy to, 578–579

Aluminum and calcium acetate, for contact dermatitis, 286

Aluminum hydroxide, macrophagic myofasciitis from. *See* Macrophagic myofasciitis.

Alveolitis, extrinsic allergic, versus asthma, 173–174

Alzheimer's disease, **103–115**
  amyloid vaccines for, 110–111
  anti-inflammatory drugs for, 109–110
  cognitive decline in, 103–104
  cytokines and, 22–23
  epidemiology of, 103
  immune response and, 106–109
    activation of, 108–109
    nonspecific innate, 106–107
    systemic, 107–108
  infections in, 111–112
  pathophysiology of, 105
  previous vaccine exposure and, 45
  stages of, 104

American cockroach. *See under* Cockroaches.

Amoxicillin, for anthrax, 715

Amylase, from plants, occupational asthma from, 238–239

Amyloid deposition, in Alzheimer's disease, 105–107
  antibodies to, 108–109

AN-1792 (vaccine), for Alzheimer's disease, 110–111

Anaphylaxis
  in egg allergy
    from influenza immunization, 634
    from measles, mumps, rubella immunization, 637–638
    from yellow fever immunization, 640–641
  in latex allergy, 211
  in vaccine allergy, 556–557, 679

Andersen microbial sampler, for bioaerosols, 346

Angioedema, in egg allergy, from measles, mumps, rubella immunization, 637–638

Animal allergens, **469–481**
  air sampling for, 472–474
  avoidance of, 476–478, 538–540
  challenge testing for, 264
  farm, 471
  immune response to, 474–476
  occupational asthma from, 240–241
  particulate, 471–474
  proteins, 471–474
  types of, 469–471

Annoyance reactions, rhinitis, 195–196

Anthrax, **711–728**
  active immunization for, vaccine for, 717–722
    composition of, 717
    dosage of, 718
    efficacy of, 718–720
    future of, 722–723
    indications for, 722
    live-spore, 718
    postexposure, 720
    production of, 717
    safety of, 720–722
    storage of, 718
  as agricultural disease, 711
  as bioweapon, 711–712
  bacteriology of, 713
  clinical description of, 712
  cutaneous
    clinical features of, 712
    diagnosis of, 714
    pathogenesis of, 714
    treatment of, 715
  diagnosis of, 714–715
  epidemiology of, 715–716
  gastrointestinal
    clinical features of, 712
    diagnosis of, 715
    treatment of, 715
  inhalational
    clinical features of, 712

diagnosis of, 714–715
pathogenesis of, 714
treatment of, 715
passive immunization for, 716–717
pathogenesis of, 713–714
prevention of, 715
toxins in, 713–714
treatment of, 715

Anti-inflammatory drugs, for Alzheimer's disease, 109–110

Antibiotics
for elderly persons, 61–63
in vaccines, allergy to, 576–577

Antibody(ies), to latex allergens, measurement of, 211, 213

α_1-Antichymotrypsin, in Alzheimer's disease, 107–108

Antifungal agents, for environmental sensitivity, 321

Antigen(s)
bacterial, in vaccines, allergy to, 579–580
overload of, in multiple vaccination, 653–655
parental concerns about, 648–649
presentation of, in elderly persons, vaccine efficacy and, 47–48

Antigen-antibody reactions, from vaccines, 557–558

Antigen-presenting cells, in transcutaneous immunization, 784, 790

Antihistamines
for contact dermatitis, 286
for rhinitis, 201–202

Antioxidants, for elderly persons, 140–141
cytokines and, 30–31

Antisera, anthrax, 716–717

Antiviral drugs, for environmental sensitivity, 321

Apoptosis, of T lymphocytes, in elderly persons, 67–71

Arid Southwest floristic zone, 366–367

Arthritis
from Lyme disease vaccine, 597
in elderly persons
psoriatic, 77–78
rheumatoid, 75–76

Arthus reaction, from vaccines, 557–558

Aspergillus, 502
allergens of, 298
environmental sensitivity from, 321
hypersensitivity from, 300, 503
occupational asthma from, 242
tricothecenes of, 302

Aspiration, in elderly persons, 58

Asthma
allergic
avoidance in. *See* Avoidance.
cockroach, 491–492
fungal, 502–503
pollen counts and. *See* Pollen counts.
thunderstorms and, 418–419
cold-adapted, live attenuated influenza vaccine in, 760
occupational
atopy and, 237
bakers', 238–239
definition of, 167, 221, 235
diagnosis of, 169–171
from high-molecular-weight substances, 242–245
from low-molecular-weight substances, 228–229
differential diagnosis of, **167–176,** 229
epidemiology of, **155–166,** 167–168
approaches to, 156–158
from high-molecular-weight substances, 235–236
from low-molecular-weight substances, 221–223, 236
historical perspectives in, 162–164
immunologic assessments in, 158
questionnaires for, 158
risk assessment in, 160–161
screening in, 161–162
spirometry in, 158–160
study designs for, 156–157
surveillance in, 161–162
surveys for, 157–158
terminology of, 155–156
evaluation of, from low-molecular-weight substances, 229–231
from high-molecular-weight substances, **235–250**
animal proteins and enzymes, 240–242
antigens causing, 238–242
atopy and, 237
bronchial hyperreactivity in, 237
diagnosis of, 242–245
mechanisms of, 235–236

plant proteins, 238–240
prognosis for, 245–246
risk factors for, 236–238
treatment of, 245–246
from irritants, 171–172
from latex, 239–240
from low-molecular-weight substances, **221–234**
causes of, 221–223
diagnosis of, 228–229
evaluation of, 229–231
information sources for, 223
pathogenesis of, 223–227
prevalence of, 221–223
risk factors for, 228
from toxic exposures, 188–189
mechanisms of, with high-molecular-weight substances, 235–236
misdiagnosis of, 172–174
odor perception and, 187
pathogenesis of, from low-molecular-weight substances, 223–227
pathophysiology of, 168
prognosis for, from high-molecular-weight substances, 245–246
rhinitis and, 194
risk factors for, 168–169
from high-molecular-weight substances, 236–238
from low-molecular-weight substances, 228
treatment of, from high-molecular-weight substances, 245–246
versus nonoccupational asthma, 171

Astigmata, taxonomy of, 443–446. *See also* Dust mites; Storage mites.

Atherosclerosis, in elderly persons, **117–132**
autoimmune disease and, 9
chronic infection in, 125–126
cytokines and, 23–25
heat shock protein 60 in, 120–127
historical considerations in, 118–120
immunohistochemical studies of, 118–120

Atopy
from vaccines, 597–598
occupational asthma and, 160–161, 237

Autoimmune disease
from vaccines, 597–598
in elderly persons, **65–82**
chronic inflammation in, 72–75
environmental factors in, 72–75
genetic factors in, 72
hypersensitivity and, 72–75
osteoarthritis in, 75
rheumatoid arthritis in, 75–76
spondyloarthropathy in, 76–78
T-cell senescence in, 66–71
treatment of, 78–79

Autoimmune theory, of environmental sensitivity, 314

Aveeno, for contact dermatitis, 286

Avoidance
in contact dermatitis, 287–288
of allergens, **533–547**
animal, 476–478, 538–540
cockroach, 494–495, 540–543
dust mite, 535–538
mold, 543–544
principles of, 533–534
of chemicals, in environmental sensitivity, 319–320

B

B lymphocytes, in elderly persons, vaccine efficacy and, 46–47

Bacillus anthracis infections. *See* Anthrax.

Bacteria, enzymes of, occupational asthma from, 241–242

Bacterial ADP-ribosylating exotoxins, as adjuvants in transcutaneous immunization, 791–793
clinical studies of, 802–804
in immunostimulant patch, 795–800
mucosal response to, 801–802
systemic immune response to, 800–801

Baits, for cockroach control, 541–542

Bakers' asthma, 238–239

Barrier creams, for contact dermatitis, 287–288

Basidiomycetes, allergens of, 299

Beds, dust mite allergens in, avoidance of, 535–538

Behavior modification, for environmental sensitivity, 323

Beryllium disease, genetic factors in, 228

Betamethasone, for contact dermatitis, 287

Bias, in risk assessment, for occupational asthma, 161

Bioaerosols, submicronic, from pollen, 392, 418

Biologic exposure indices, for toxic substances, 180

Biopsy, skin, in contact dermatitis, 279

Birch pollen, forecasting of, 428–429

Bla g cockroach allergens
  cross-reactivity of, 489
  description of, 487–488
  sensitization to, 490

Bleeding disorders, vaccinations in, 622–623

Body composition, of elderly persons, cytokines and, 20

Bos d allergens. *See* Animal allergens.

Breast cancer, in elderly persons, 88

Bromelain, occupational asthma from, 241

Bronchial challenge testing. *See* Challenge testing.

Bronchial hyperreactivity, in occupational asthma, 237

Building-related illness
  fungal, **291–309**
  versus environmental sensitivity, 317

Bulk samples, for fungal sampling, 525

Burkard samplers, for bioaerosols, 343–344, 346–347

Burow's solution, for contact dermatitis, 286

Button Aerosol Sampler, 350

C

California Lowland floristic zone, 365–366

Can f allergen. *See* Animal allergens.

Cancer
  immunodeficiency in, vaccinations in, 618, 620
  susceptibility to. *See* Tumor(s), susceptibility to, in elderly persons.

Cardiovascular disease, in elderly persons, cytokines and, 23–25

Case-control studies, in epidemiology, 157

Case-series studies, in epidemiology, 157

Cat allergens. *See* Animal allergens.

Cattle allergens. *See* Animal allergens.

CD28 (costimulatory molecule), in elderly persons
  tumor susceptibility and, 96–98
  vaccine efficacy and, 48

CD40, in Alzheimer's disease, 107

Cellular (replicative) senescence
  autoimmune disease and, 67
  vaccine efficacy and, 49–50

Central Plains floristic zone, 363–364

Centrifugal impactors, for bioaerosol sampling, 348–349

Cephalosporins, for infections, in elderly persons, 63

Cetirizine, for rhinitis, 201

Challenge testing
  in latex allergy, 213
  in occupational asthma, 170, **251–267**
    biologic, 243–244
    from high-molecular-weight substances, 243–245
    from low-molecular-weight chemicals, 230
    in epidemiologic studies, 159–160
    natural, 243–244
    nonspecific, 252–257
      bronchoconstrictor agents for, 254–255
      interpretation of, 255–256
      precautions for, 252–254
      procedures for, 255–256
      pulmonary function values for, 254
      serial monitoring in, 256–257
    specific, 257–264
      aerosol, 245, 262–263
      at workplace, 263–264
      chamber for, 263
      dust, 245, 262
      false results in, 262
      for animal exposure, 264
      from high-molecular-weight substances, 244
      preparation for, 257–258
      procedures for, 258–262
      vapor, 263
  in rhinitis, 198–199

Chemicals
  asthma from, 221–234
  contact dermatitis from. *See* Contact dermatitis, occupational.
  rhinitis from. *See* Rhinitis, occupational.
  sensitivity to. *See* Environmental sensitivity.
  toxic. *See* Toxic exposures.

Chemokines
  in Alzheimer's disease, 107
  in asthma, 227

Chemotherapy, immunodeficiency in, vaccinations in, 618, 620

Chlamydia pneumoniae infections, atherosclerosis in, 125–126

Cholera toxin, as adjuvant in transcutaneous immunization, 789, 791–792
  mucosal immune response to, 801–802
  systemic immune response to, 800–801

Cholera vaccine
  allergy to, 578
  components of, 561

Chronic fatigue syndrome
  macrophagic myofasciitis and, 706
  versus environmental sensitivity, 317

Chronic obstructive pulmonary disease, versus asthma, 172

Ciprofloxacin, for anthrax, 715

Cities, plants in. *See* Urban jungle.

Cladosporium, allergens of, 298–299

Cleaning methods, for allergen control
  animal, 476–478, 539–540
  cockroach, 542–543
  dust mite, 535–538

Climate. *See* Floristic zones; Meteorologic variables.

Clinical-case studies, in epidemiology, 157

Clinical Dementia Rating, for Alzheimer's disease, 104

Coccidioidomycosis, occupational, 300

Cockroaches, **483–499**
  allergens of
    American, 488–489
    asthma due to, 491–492
    avoidance of, 540–543
    characterization of, 486–489, 540–541
    control of, 492–494, 540–543
    cross-reactivity among, 489
    fecal, 486
    German, 487–488
    reactions to, diagnosis and treatment of, 494–495
    sensitization to, 489–491
    whole-body, 486
  American, 484, 486–489
  characterization of, 484–486
  German, 484–489
  inspection for, 541
  species of, 483
  taxonomy of, 483–484

Cognitive decline, in Alzheimer's disease, 103–104

Cohort studies, in epidemiology, 157

Cold environment, dust mites in, 462–463

Colonization, of fungi, in buildings, 521–522

Colorectal cancer, in elderly persons, 88

Common leukocyte antigen, in contact dermatitis, 272

Complement activation, in Alzheimer's disease, 106–107

Conditioned-response theory, of environmental sensitivity, 315

Congestive heart failure, versus asthma, 174

Contact dermatitis, occupational, **269–290**
  antigens causing, 281–284
  diagnosis of, 274–276, 279–281
  epidemiology of, 269–271
  from latex exposure, 209–210
  history in, 276–277
  information resources for, 288–289
  pathophysiology of, 271–273
  physical examination in, 277–279
  prevention of, 288
  prognosis for, 282, 284–286
  risk factors for, 273–274
  treatment of, 286–288

Contact urticaria, occupational
  from latex exposure, 210
  pathophysiology of, 272–273
  physical examination in, 279

Corrosive substances, rhinitis from, 195–196

Corticosteroids
  for Alzheimer's disease, 109–110
  for contact dermatitis, 286
  in nasal sprays, for rhinitis, 201

Counseling, for environmental sensitivity, 324

Cross-sectional studies, in epidemiology, 157

Cryptococcosis, occupational, 300–301

Culture
  of bioaerosol samples, 339–340
  of fungi, 522–523, 526–527

Cyclex-d sampler, for bioaerosols, 345

Cytokines
  in asthma, 226–227
  in contact dermatitis, 272
  in elderly persons, **15–39**
    Alzheimer's disease and, 22–23, 107–108
    anti-inflammatory, 15–16
    antioxidants and, 30–31
    autoimmune disease and, 78–79
    body composition and, 20
    cardiovascular disease and, 23–25
    chronic disease and, 22–27

chronic elevations of, 18–22
diabetes mellitus and, 26
exercise and, 29–30
frail, 26–27
hypertension and, 21
in acute-phase response, 17–18
infections and, 20–21
mortality and, 27–29
polymorphisms in, 21–22
pro-inflammatory, 15–16
smoking and, 21
statins and, 30
in gelatin hypersensitivity, 573

Cytomegalovirus infections, in elderly persons
atherosclerosis in, 125–126
immune-risk phenotype and, 5–6

D

Dampness, indoor, health effects of, 505

Dander, animal. *See* Animal allergens.

Dehydroepiandrosterone, for elderly persons, 9

Delayed-type hypersensitivity, to vaccines, 558

Dementia, Alzheimer's. *See* Alzheimer's disease.

Dermatitis, contact. *See* Contact dermatitis.

Dermatophagoides. *See* Dust mites.

Dermatophytoses, 501–502
occupational, 301

Detergents, skin damage from, contact dermatitis after, 274

Detoxification, for environmental sensitivity, 321

Diabetes mellitus, in elderly persons, cytokines and, 26

Diet, for environmental sensitivity
elimination, 320
supplements in, 321–322

Diisocyanates
asthma from, 223, 225–227
rhinitis from, 196–197

Diphenylmethane diisocyanate, occupational asthma from, 263

Diphtheria, tetanus, acellular pertussis vaccine
allergy to, 578, 581
gelatin in, allergy to, 571–572
poliovirus vaccine with, 652–653
safety of, 591–593

Diphtheria, tetanus toxoids, components of, 560

Disability, in elderly persons, cytokines and, 26–27

Dog allergens. *See* Animal allergens.

Doxycycline, for anthrax, 715

Drug(s), for elderly persons, immunodeficiency due to, 134

Dryvax. *See* Smallpox vaccine.

DTaP vaccine. *See* Diphtheria, tetanus, acellular pertussis vaccine.

Dust, fungi in, 513–514, 525–526

Dust challenge test, in occupational asthma, 245, 262

Dust mites, **443–468**
allergens of, avoidance of, 535–538
anatomy of, 452–453
geographic distribution of, 446–450
humidity requirements of, 459–462
in public places, 450–451
life cycle of, 454–456, 458–459
morphology of, 451–452
physiology of, 452–453
prevalence of, 446–450
reproduction of, 453–458
seasonal fluctuations in, 446, 449
species related to, 444–446
taxonomy of, 443–444
thermal tolerance of, 462–463
water balance of, 459–462

E

Eastern Agricultural floristic zone, 362–363

Eczema vaccinatum, from smallpox vaccine, 733–734

Edema factor, in anthrax, 713–714

Egg allergy
vaccine administration procedure with, 569–570, **633–646**
influenza
inactivated, 633–637
live, attenuated, cold-adapted, 637
measles, mumps, rubella, 637–639
rabies, 642–643
raw egg products and, 641–642
smallpox, 643
yellow fever, 639–642
vaccine reactions in
influenza, 566–567
measles, mumps, rubella, 559, 566
skin testing for, 567–569
yellow fever, 566

Elderly persons
Alzheimer's disease in. *See* Alzheimer's disease.
atherosclerosis in, 9, 23–25, **117–132**
autoimmune disease onset in, **65–82**
cold-adapted, live attenuated influenza vaccine for, 760
cytokines in, **15–39**
immune response in. *See* Immune response, in elderly persons.
infections in. *See* Infections, in elderly persons.
tumor susceptibility in, **83–102**
vaccines for, 2, **41–55**

Embolism, pulmonary, versus asthma, 174

Employment, disorders related to. *See* Occupational disorders.

Encephalitis
from smallpox vaccine, 733–734
Japanese. *See* Japanese encephalitis virus.

Environmental controls
for latex allergy, 214–215
for occupational asthma, from high-molecular-weight substances, 245–246
for rhinitis, 200–201

Environmental factors
in autoimmune disease, in elderly persons, 72–75
in tumor susceptibility, in elderly persons, 87–88

Environmental sensitivity, **311–328**
clinical features of, 313
definition of, 311–312
diagnosis of, 317–319
epidemiology of, 317
pathogenesis of, 313–316
treatment of, 319–324
versus other environmental conditions, 317

Enzyme(s), occupational asthma from, 241–242

Enzyme-linked immunosorbent assay
for fungi, 523
in occupational asthma, 243

Equ c allergens. *See* Animal allergens.

Erythema, in contact dermatitis, 274

Escherichia coli, heat-labile toxin of (LT), as adjuvant in transcutaneous immunization, 785–788, 791–792
clinical studies of, 802–804
in immunostimulant patch, 795–800
mucosal response to, 801–802
safety of, 792–795
systemic immune response to, 800–801

Ethical issues, in infection treatment, in elderly persons, 62

Euroglyphus maynei. See Dust mites.

Exercise, in elderly persons
cytokines and, 29–30
for immune system enhancement, 141–142

Extrinsic allergic alveolitis, versus asthma, 173–174

F

Farmers, occupational asthma in, 241

Farmer's lung, precipitin-negative, 301–302

Fatigue, in macrophagic myofasciitis, 700, 702–703

Fel d allergen. *See* Animal allergens.

Fever, in elderly persons, 58–59

Fexofenadine, for rhinitis, 201

Fibromyalgia, in macrophagic myofasciitis, 702

Filtration samplers, for bioaerosol sampling, 350–351

Financial considerations, in infection treatment, in elderly persons, 62

Finger challenge test, for latex allergy, 213

Fish processing, occupational asthma from, 240–241

Florida Subtropical floristic zone, 367–368

Floristic zones, **357–369**
Arid Southwest zone, 366–367
California Lowland zone, 365–366
Central Plains zone, 363–364
definition of, 358–360
Eastern Agricultural zone, 362–363
Florida Subtropical zone, 367–368
Great Basin zone, 367
map of, 360
Northern Forest zone, 360–362
Northwest Coastal zone, 365
Rocky Mountain zone, 364–365
Southeastern Coastal Plain zone, 367

Flour, occupational asthma from, 238–239

Fluoroquinolones, for anthrax, 715

Food allergens, latex allergen cross reactions with, 206–207

Food-elimination diet, in environmental sensitivity, 320

Frailty, in elderly persons
cytokines and, 26–27
infections in, 61

Fumes, toxic, exposure to, 178

Fumonisins, toxicity of, 302

Functional disability, in elderly persons, cytokines and, 26–27

Fungi
allergic reactions to, 297–300, 304, 321
avoidance of, 543–544
culture of, 522–523
environmental sensitivity from, 321
in indoor environment, **291–309**
allergic sensitization to, 297–300, 304
assessment of, 293–294
common species of, 293
ecology of, 292
health effects of, 295–302, 304–305
hypersensitivity states from, 297–300
infections from, 300–301
irritant effects of, 295, 304
mycotoxicosis from, 301–302, 304
nonspecific respiratory symptoms from, 295–297, 305
occupational, 294–295
odors of, 295
psychogenic effects of, 302
Stachybotrys, 302–305
versus outdoor levels of, 292–293
indoor exposure to, **501–518**
allergens involved in, 503
assessment of, **519–531**
colonization in, 521–522
dampness and, 505
data analysis of, 514
fungal populations involved in, 512–514
hypersensitivity diseases in, 502–503
infections in, 501–502
measures of, 509–512
routes of, 507–509
sources of, 505–507
toxic effects of, 504–505
occupational asthma from, 241–242
spore counts and. *See* Spore counts.

Fusarium, tricothecenes of, 302

G

Gases, toxic, exposure to, 178

Gelatin, in vaccines, allergy to, 570–573

Genetic factors
in autoimmune disease, in elderly persons, 72
in immunosenescence, in elderly persons, 9
in occupational asthma, 161, 228
in tumor susceptibility, in elderly persons, 87–88

Geographic distribution
of aeroallergens. *See* Floristic zones.
of dust mites, 446–450
of pollen counts, 391
of spore counts, 392

German cockroach. *See under* Cockroaches.

Germinal center reaction, of B lymphocytes, in elderly persons, vaccine efficacy and, 46–47

Global Deterioration Scale, for Alzheimer's disease, 104

Gloves, for contact dermatitis, 287–288

Glucans, in fungi, irritant effects of, 295

Glucocorticoids, for Alzheimer's disease, 109–110

Glutaraldehyde, occupational asthma from, 223, 226

Grain fever syndrome, 301–302

Grass pollen, forecasting of, 427–428

Gravity collectors, for pollen and spore counts, 393

Great Basin floristic zone, 367

Greenburg-Smith impinger, for bioaerosol sampling, 349–350

Growth hormone, for elderly persons, 9

Guillain-Barré syndrome, from influenza vaccine, 591

Gulf War syndrome, versus environmental sensitivity, 706

H

Haemophilus influenzae, vaccines for
allergy to, 583
components of, 563–564
safety of, 594

Hardiness zones, of plants, 358–360

Health care workers, latex allergy in, 196, 208–209, 239–240

Heart failure, versus asthma, 174

Heat shock protein(s), in elderly persons, 30–31

Heat shock protein 60, in atherogenesis, 120–127

Heat tolerance, of dust mites, 462–463

Helicobacter pylori infections, in elderly persons, atherosclerosis in, 125–126

Hematopoietic stem cell transplantation, vaccinations in, 613–616

Hemodialysis, vaccinations in, 623

Hemophilia, vaccinations in, 622–623

Hepatitis A vaccine
components of, 562
for elderly persons, 44

Hepatitis B vaccine
allergy to, 583
components of, 565
in immunodeficiency, 624
safety of, 591

Herpes zoster
after varicella vaccination, 595
in elderly persons, 136

Hev 6 allergens, of rubber latex, 206

Hexamethylene diisocyanate, occupational asthma from, 263

Hirst sampler, for bioaerosols, 343

Histamine challenge test, in occupational asthma, 170, 244
in epidemiologic studies, 159
procedure for, 255–256
versus methacholine test, 254

Histoplasmosis, occupational, 300

HIV infection. *See* Human immunodeficiency virus infection.

Hormones, for environmental sensitivity, 322

Horse allergens. *See* Animal allergens.

House dust mites. *See* Dust mites.

Human immunodeficiency virus infection
cold-adapted, live attenuated influenza vaccine in, 760
in elderly persons, 61, 136–137
vaccines for, 44
vaccinations in
contraindicated, 608–609
for children, 610–611
immune response to, 606–607, 609
in elderly persons, 44
multiple, 656
pneumococcal, 612–613
smallpox, 737

Human leukocyte antigens
in contact dermatitis, 271
in occupational asthma, 161, 228

Humidity
aeroallergen count and, 413–414
fungal growth and, 519
in buildings, fungal growth in, 295, 297
in floristic zones. *See* Floristic zones.
requirements of, for dust mites, 459–462

Humoral immunity, in meningococcal disease, 768–769

Hypersensitivity pneumonitis
fungi in, 300
versus asthma, 173–174

Hypersensitivity reactions
in autoimmune disease, in elderly persons, 72–75
to fungi, 502–503
to vaccines, 556–558. *See also* Vaccine(s), allergy to.
type IV
in contact dermatitis, 271
to fungi, 297–300

Hypertension, in elderly persons, cytokines and, 21

Hypotonic–hyporesponsive episode, from vaccines, 582, 584

I

Immune reaction, rhinitis in, 195–196

Immune response
in elderly persons, **1–13, 133–148**
cancer and. *See* Tumor(s), susceptibility to, in elderly persons.
enhancement and reconstitution of, 8–9, 137–142
exercise in, 141–142
intravenous immunoglobulin for, 139
nutrition in, 139–141
vaccines for, 139
factors affecting, 133–135
immune-risk phenotype in, 5–6, 9
infections and, 60, 135–137
studies on
death causes, 2
in vitro culture models of, 7
interpretation of, 3–5
laboratory parameters, 2–3
longitudinal, 5–6
vaccine efficacy, 2
tumor susceptibility and. *See* Tumor(s), susceptibility to, in elderly persons.
with Alzheimer's disease, 106–109

in transcutaneous immunization, adjuvants and, 800–801
to cold-adapted, live attenuated influenza vaccine, 747–749

Immune-risk phenotype, in elderly persons, 5–6, 9

Immunization. *See* Vaccine(s).

Immunoassays, for latex allergens, 211, 213

Immunochemical assays, of bioaerosol samples, 340–341

Immunodeficiency
from vaccines, 597–598
infections in, 501–502, 603–605
meningococcal disease in, 767
smallpox vaccine contraindicated in, 731
tumor incidence in, 89–91
vaccinations in, **603–631**
general recommendations for, 607
hepatitis B virus, 624
in bleeding disorders, 622–623
in chronic renal failure, 623
in hematopoietic stem cell transplantation, 613–616
in HIV infection, 607–613
in pregnancy, 620–622
in severe immunodeficiency, 617
in solid organ transplantation, 616–619
MMR, 624
multiple, 656
principles of, 603–607
travel, 625
varicella, 625

Immunoglobulin(s), intravenous
for environmental sensitivity, 322
for immune system enhancement, in elderly persons, 139
for measles exposure, 624

Immunoglobulin E
in animal allergen exposure, 474
in asthma, 168, 235–236
in fungal allergy, 502–503, 512
in fungal lung disease, 300
in gelatin allergy, 571–573

Immunologic assessments, for epidemiologic studies, in occupational asthma, 158

Immunological hypothesis, for atherosclerosis, 120–127

Immunosenescence. *See* Immune response, in elderly persons.

Immunosuppressive therapy, for autoimmune disease, in elderly persons, 78

Immunotherapy
for cancer, in elderly persons, 91–93
for cockroach allergy, 495

Immunotoxic theory, of environmental sensitivity, 314–315

Impingers, liquid, for bioaerosol sampling, 349–350

Incidence, in epidemiology, definition of, 155

Indoor allergens
animal danders, **469–481**
cockroach. *See* Cockroaches.
dust mite. *See* Dust mites.
fungal, **501–518, 519–531**
sampling for, 338

Industrial hygiene survey, in toxic exposures, 181–182

Inertial impactors, for bioaerosol sampling, 341, 343

Infections
fungal, 501–502
in elderly persons, **57–64**
atherosclerosis risk in, 125–126
coexisting diseases with, 61
cytokines and, 20–21
factors contributing to, 57–61
fever in, 58–59
immune response in, 60, 135–137
in Alzheimer's disease, 111–112
in antibody response deficits, 60
in mucocutaneous barrier breakdown, 60
in nursing homes, 61–62
in swallowing defects, 58
in T-lymphocyte defects, 60
multiple, 60–61
prevention of
with immunosenescence interventions, 8–9
with infection control measures, 62
skin, 58
treatment of, 61–63
urinary, 57–58

Inflammation, in Alzheimer's disease, 106

Inflammatory mediators
in pollen reactions, 395–397
in urticaria, 272–273

Inflammatory myopathy with abundant macrophages, versus macrophagic myofasciitis, 698–699

Influenza
in elderly persons
immune system effects of, 135–136
vaccines for, 42–43

naturally acquired immunity to, 746–747
vaccines for
allergy to, 566–567, 584
components of, 562
in elderly persons, 42–43
inactivated, egg allergy and, 633–637
live, attenuated, cold-adapted, **743–764**
administration of, 745–746
characteristics of, 745–746
development of, 744–745
efficacy and effectiveness of, 747–749, 754–758
egg allergy and, 637
genetic stability of, 760
heterotypic antibody data on, 752–753
immunogenicity of, 749–751
interference between strains in, 751–752
safety of, 756, 759–760
versus immunity from natural infection, 746–747
virus transmission from, 761
safety of, 590–591

Ingestion, of fungal allergens, 509

Inhalation, of fungal allergens, 507–508

Insecticides, for cockroach control, 492–494, 541–543

Insects, pollen dispersal by, 376–377

Interferon(s), in Alzheimer's disease, 107–108

Interleukin(s)
in Alzheimer's disease, 107–108
in asthma, 226–227
in gelatin hypersensitivity, 573

Interleukin 1, in elderly persons
antioxidants and, 30–31
hypertension and, 21
in acute-phase response, 17–18
infections and, 20–21
polymorphisms in, 21–22
pro-inflammatory effects of, 15–16

Interleukin 2, for cancer, in elderly persons, 91–92

Interleukin 6, in elderly persons
Alzheimer's disease and, 22–23
anti-inflammatory effects of, 16
antioxidants and, 30–31
body composition and, 20
cardiovascular disease and, 23–25
chronic disease and, 22–27
chronic elevations of, 18–22
diabetes mellitus and, 26
exercise and, 29–30
frail, 26
in acute-phase response, 17–18
infections and, 20–21
mortality and, 28–29
polymorphisms in, 21–22
smoking and, 21
statins and, 30

Interleukin 10, in elderly persons, polymorphisms in, 21–22

Intranasal vaccines, influenza. *See* Influenza, vaccines for, live, attenuated, cold-adapted.

Ipratropium bromide, for rhinitis, 201

Irritant contact dermatitis, occupational
antigens causing, 281–283
diagnosis of, 274–276, 279–281
epidemiology of, 269–271
from latex exposure, 210
pathophysiology of, 271–273
physical examination in, 277–279
prevention of, 288
prognosis for, 282, 284–286
treatment of, 286–288
versus allergic contact dermatitis, 285

Irritation
from indoor fungi, 295, 304
from toxic substances, of respiratory tract, 186–188
in asthma, 171–172
in fungal exposure, 504–505
in rhinitis, 195–196

Isocyanate challenge test, in occupational asthma, 263

J

Japanese encephalitis virus, **663–695**
clinical features of, 664–665
epidemiology of, 663–664
vaccines for
allergy to, 578, 670–680
case control studies of, 682–685
questionnaire studies of, 680–682
reporting from various countries, 671–680
components of, 563
neurologic reactions to, 685–689
types of
inactivated mouse-brain–derived, 665–667

inactivated primary hamster-kidney-cell–derived, 667–668
live attenuated, 668–670
new, 670

Juniperus ashei (mountain cedar pollen), forecasting of, 431–439

K

Kidney
failure of, vaccinations in, 623
transplantation of, vaccinations in, 616–619

Koebner phenomenon, occupational, 274

L

Laboratory workers, with animals, occupational asthma in, 240–241, 264

Landscaping, in cities. *See* Urban jungle.

Langerhans cells
in contact dermatitis, 271–272
in transcutaneous immunization
adjuvants acting on, 792–793
function of, 784
immunostimulant patch and, 795

Laryngoscopy, in vocal cord dysfunction, 173

Latex allergy
in vaccine administration, 577
occupational, **205–219,** 239–240
allergens in, 206–207
anaphylaxis in, 211
clinical features of, 209–211
diagnosis of, 211–213
epidemiology of, 207–209
in health care workers, 196, 208–209, 239–240
in manufacturing workers, 208
latex-safe environments and, 213–214
management of, 213–215
prevention of, 214–215
respiratory reactions in, 210–211
rubber chemistry and, 206
rubber processing and, 205
skin reactions in, 209–210

Lead acetate, for contact dermatitis, 286

Lethal factor, in anthrax, 713–714

Leukemia, immunodeficiency in, vaccinations in, 618, 620

Lichen planus, occupational, 281

Liquid impingers, for bioaerosol sampling, 349–350

Liver, transplantation of, vaccinations in, 616–619

Loratadine, for rhinitis, 201

Lotions, for contact dermatitis, 287

Lung cancer, in elderly persons, 87

Lyme disease vaccine
components of, 565
safety of, 596–597

Lymph nodes, Langerhans cells migration to, in transcutaneous immunization, 785, 793, 795–797

Lymphoma, immunodeficiency in, vaccinations in, 618, 620

M

Macrophagic myofasciitis, from aluminum hydroxide adjuvants, **697–709**
chronic fatigue syndrome and, 706
clinical manifestations of, 700, 702–703
differential diagnosis of, 698
Gulf War syndrome and, 706
historical review of, 697–699
in deltoid muscle, 703–704
pathology of, 697–699, 701–702
pathophysiology of, 705–706
susceptibility to, 704

Malnutrition, in elderly persons
immunodeficiency in, 134
treatment of, 137–141
with Alzheimer's disease, 112

Material safety data sheets, for toxic substances, 183

Measles, mumps, rubella vaccine
allergy to, 559, 566, 582
components of, 561
egg allergy and, 637–639
gelatin in, allergy to, 571–572
in HIV infection, 609
in immunodeficiency, 624
infections after, 655
safety of, 595–596

Memory impairment, in Alzheimer's disease, 103–104

Meningitis
in anthrax, 712
meningococcal. *See* Meningococcal disease.

Meningococcal disease, **765–782**
bacteriology of, 765–766

diagnosis of, 767–768
epidemiology of, 766–767
in immunodeficiency, 767
mechanisms of immunity to, 768–770
pathogenesis of, 767
serogroups of, 765
significance of, 765
vaccines for
booster doses of, response to, 770
carriage effects of, 773–774
components of, 564
conjugate, 774–775
development of, 769
efficacy of, 770–774
in military recruits, 770–771
in outbreak control, 771–772
in pediatric patients, 770–771, 775–776
recommendations for, 774–778
revaccination with, 776
serogroup A, 771–777
serogroup B, 777–778
serogroup C, 769–771, 774–777

Meteorologic variables, **411–422**
in pollen counts, 413–416
in spore counts, 416–418
season definition, 412–413
submicronic particle release and, 392, 418
thunderstorms, 418–419

Methacholine challenge test, in occupational asthma, 170, 244
advantages of, 254–255
from low-molecular-weight chemicals, 230
guidelines for, 253
in epidemiologic studies, 159
interpretation of, 255–256
procedure for, 255–256
serial monitoring in, 256–257

Microbial volatile organic compounds, health effects of, 504–505

Microorganisms
environmental sensitivity from, 316
occupational asthma from, 241–242

Microscopy
of bioaerosol samples, 339
of fungi, 523

Mineral supplements
for elderly persons, 140–141
for environmental sensitivity, 321–322

Mini-mental status examination, for Alzheimer's disease, 104

Mists, toxic, exposure to, 178

Mites
dust. *See* Dust mites.
taxonomy of, 443–444

MMR vaccine. *See* Measles, mumps, rubella vaccine.

Mold. *See* Fungi.

Mortality
from smallpox vaccine, 733
in elderly persons
cytokines and, 27–29
immunosenescence and, 2

Mountain cedar pollen, forecasting of, 431–439

Mouse allergens. *See* Animal allergens.

MSDSs (material safety data sheets), for toxic substances, 183

Mucosal immune response, in transcutaneous immunization, adjuvants and, 801–802

Mucosal vaccines, for elderly persons, 45–46

Multiple chemical sensitivity. *See* Environmental sensitivity.

Mumps vaccine, in MMR vaccine. *See* Measles, mumps, rubella vaccine.

Mus allergens. *See* Animal allergens.

Myalgia, in macrophagic myofasciitis, 700, 702–703

Mycotoxicosis, 301–305

Mycotoxins
detection of, 511–512
health effects of, 504

Myocardial infarction, in elderly persons, cytokines and, 23–25

Myofasciitis, macrophagic. *See* Macrophagic myofasciitis.

Myopericarditis, from smallpox vaccine, 733–734, 737

N

Nasal challenge studies, for rhinitis, 198–199

Nasal sprays, for rhinitis, 201

National Allergy Bureau, pollen and spore count statistics of, 393–394

Natural killer cells, in Alzheimer's disease, 107–108

Natural rubber allergy. *See* Latex allergy.

Neisseria meningitidis infections. *See* Meningococcal disease.

Neomycin, in vaccines, allergy to, 576–577

Neonates, immune system of, antigen exposure to, 649

Neurofibrillary tangles, in Alzheimer's disease, 105–106

Neurologic reactions, to Japanese encephalitis vaccine, 685–689

Neurotoxic theory, of environmental sensitivity, 315

Neutralization therapy, for environmental sensitivity, 320–321

Nonsteroidal anti-inflammatory drugs, for Alzheimer's disease, 109–110

Northern Forest floristic zone, 360–362

Northwest Coastal floristic zone, 365

Nose, influenza vaccine administered through. *See* Influenza, vaccines for, live, attenuated, cold-adapted.

Nuclear factor kappa-B, in elderly persons, tumor susceptibility and, 98–99

Nuclear factor of activated T cells, in elderly persons, tumor susceptibility and, 98–99

Nutrition
  for immune system reconstitution, 137–141
  inadequate. *See* Malnutrition.

O

Occupational disorders
  asthma. *See* Asthma, occupational.
  contact dermatitis, 209–210, **269–290**
  environmental sensitivity, **311–328**
  fungal contamination and, **291–309**
  latex allergy, **205–219,** 239–240
  rhinitis, **193–203,** 210–211
  toxic exposures, **177–191**

Occupational Safety and Health Administration
  material safety data sheet requirements of, 183
  threshold limit values of, 182–183

Odor perception, in toxic exposures, 184–186

Ogren Plant Allergy Scale, 384–385

Ointments, for contact dermatitis, 287

Olfactory sensation, in toxic exposures, 184–186

Olive pollen, forecasting of, 429–430

Organic dust toxic syndrome, 301–302

Ornamental plants, pollen from, in cities, 381–382

Osteoarthritis, autoimmune component of, in elderly persons, 75

Oxidative stress, in elderly persons, vaccine efficacy and, 50

P

Pain, in macrophagic myofasciitis, 700, 702–703

Particulates, toxic, exposure to, 177–178

Patch, for transcutaneous immunization. *See* Transcutaneous immunization.

Patch testing
  in contact dermatitis, 280–281
  in latex allergy, 211–212

Peak expiratory flow measurement, in occupational asthma, 159–160, 170, 256–257

PELs (permissible exposure limits), for toxic substances, 182

Penicillin, for anthrax, 715

Penicillium
  allergens of, 299
  hypersensitivity pneumonitis from, 300

Per a cockroach allergens, 487–489

Permissible exposure limits, for toxic substances, 182

Perspiration, contact dermatitis related to, 274

Pertussis vaccine, in DTaP vaccine. *See* Diphtheria, tetanus, acellular pertussis vaccine.

Pet allergens. *See* Animal allergens.

Petrolatum, for contact dermatitis, 287

Plague vaccine, allergy to, 578

Plant(s)
  enzymes of, occupational asthma from, 241
  floristic zones of. *See* Floristic zones.
  in cities. *See* Urban jungle.
  proteins of, occupational asthma from, 238–240

Pneumococcal vaccines
  allergy to, 584
  components of, 564–565
  in HIV infection, 612–613

Pneumonia, in elderly persons, 58
  in Alzheimer's disease, 111–112

Pneumonitis, hypersensitivity
fungi in, 300, 503
versus asthma, 173–174

Pneumotachometry, in rhinitis, 199

Poison exposures. *See* Toxic exposures.

Poliovirus vaccine
allergy to, 583
combination
diphtheria, tetanus, acellular pertussis vaccine with, 652–653
for several serotypes, 652–653
components of, 563
safety of, 593–594

Pollen counts, **389–410**
aerobiology of, 390–391
controlled-exposure studies of, 403–404
dose response to, 404–405
floristic zones and. *See* Floristic zones.
forecasting of, **423–442**
birch, 428–429
grass, 427–428
long-term, 426–427
mountain cedar, 431–439
oak, 424
olive, 429–430
principles of, 423–426
ragweed, 424–425, 430–431
seasonal, 426
short-term, 426
types of, 426–427
geographical variation in, 391
health effects and, 394–400
hospital admissions and, 402–403
interpretation of, 405–406
lag time in reporting, 394
meteorologic variables in, 413–416
natural-exposure studies of, 401–403
pollen size and, 391
related to human exposure, 393–394
reporting of, 394
sampling methods for, 393–394
seasonal variation in, 390, 412–413
submicronic bioaerosols and, 392, 418

Polymerase chain reaction, in bioaerosol sample analysis, 340

Polymorphonuclear leukocytes, function of, in elderly persons, 60

Precipitation
aeroallergen count and, 413–414
floristic zones and. *See* Floristic zones.

Predictive values, in epidemiology, definition of, 156

Prednisone, for contact dermatitis, 286

Pregnancy, vaccinations in, 620–622

Presenilin mutations, Alzheimer's disease in, 105

Prevalence, in epidemiology, definition of, 155

Prevalence studies, in epidemiology, 157

Prick tests, in contact dermatitis, 281

Prostate cancer, in elderly persons, 87–88

Proteasomes, in elderly persons, vaccine efficacy and, 51

Protective antigen, in anthrax, 713–714
for active immunization, 717, 719
for passive immunization, 716–717

Protective equipment, for occupational exposures, evaluation of, 179

Protein(s), occupational asthma from, animal, 240–241

Protein contact dermatitis, in latex exposure, 210

Proteins, occupational asthma from, plant, 238–240

Provocation–neutralization tests, for environmental sensitivity, 318

Provocation studies. *See* Challenge testing.

Pruritus, in contact dermatitis, 274

Psoriasis
contact dermatitis related to, 274
Koebner phenomenon in, 274

Psoriatic arthritis, in elderly persons, 77–78

Psychogenic theories
of environmental sensitivity, 315–316
of fungal health effects, 302

Psychologic stress, in elderly persons, vaccine efficacy and, 50

Psychopharmacology, for environmental sensitivity, 323

Psychosocial issues, in elderly persons, immunodeficiency due to, 134–135

Psychotherapy, for environmental sensitivity, 323

Public buildings, dust mite allergens in, 450–451

Pulmonary embolism, versus asthma, 174

Pulmonary function testing, in occupational asthma, 170
in bronchial challenge tests
nonspecific, 254–257
specific, 258–262
in epidemiologic studies, 158–160

Q

Questionnaires, for epidemiologic studies, in occupational asthma, 158

R

Rabies vaccine
allergy to, 578, 580
components of, 563
egg allergy and, 642–643

Radioimmunosorbent assay, in occupational asthma, 243

Ragweed pollen, forecasting of, 424–425, 430–431

Rash
after varicella vaccination, 595
contact. *See* Contact dermatitis.

Rat allergens. *See* Animal allergens.

RCS sampler, for bioaerosols, 348–349

Reactive airway dysfunction syndrome, occupational, 171–172, 188–189
from low-molecular-weight chemicals, 221

Relative humidity requirements, of dust mites, 459–462

Replicative (cellular) senescence
autoimmune disease and, 67
vaccine efficacy and, 49–50

Respirators, for occupational exposures, evaluation of, 179

Respiratory syncytial virus vaccines, for elderly persons, 43–44

Respiratory tract
fungi effects on, 295–297, 305
toxic exposures to
anatomic considerations in, 184
exposure assessment in, 181–183
injury in, 188–189
mycotoxins, 305
odor perception and, 184–186
patient evaluation in, 178–181
types of, 177–178

Rheumatoid arthritis, in elderly persons, 75–76

Rhinitis
in cockroach allergy, 490
occupational, **193–203**
asthma and, 194
causes of, 195–197
classification of, 195–196
definition of, 194
diagnosis of, 197–199
in latex allergy, 210–211
physiology of, 194–195
prevention of, 200–201
rhinomanometry in, 199–200
treatment of, 201–202
pollen counts and. *See* Pollen counts.

Rhinomanometry, in rhinitis, 199–200

Rocky Mountain floristic zone, 364–365

Rotating-arm impactors, for bioaerosol sampling, 347–348

Rotavirus vaccine, safety of, 594–595

Rotorod sampler, for bioaerosols, 348

Rotoslide sampler, for bioaerosols, 347

Rubber allergy. *See* Latex allergy.

Rubella vaccine, in MMR vaccine. *See* Measles, mumps, rubella vaccine.

S

Sampling
for airborne biologic particles. *See* Air sampling.
for fungi, 519–530
air, 526–527
bulk samples in, 525
data generated in, 527–528
dose versus health effects and, 521–522
laboratory credentials in, 529
medical decisions resulting from, 529–530
personnel credentials for, 528–529
settled dust samples in, 525–526
swabs in, 524–525
tape slides in, 523–524
types of, 522–523
wipes in, 524–525

Sartorius Sampler, for bioaerosols, 350–351

SAS samplers, for bioaerosols, 347

Schools
animal allergens in, 538–539
dust mite allergens in, 451

Scratch tests, in contact dermatitis, 281

Screening, for occupational asthma, 161–162

Seafood processing, occupational asthma from, 240–241

Selenium supplementation, in elderly persons, 140–141

Senescence, replicative (cellular)
autoimmune disease and, 67
vaccine efficacy and, 49–50

Senile plaques, in Alzheimer's disease, 105–106

Sensitivity, in epidemiology, definition of, 155–156

Sensitization
in contact dermatitis, 271
to cockroach allergens, 489–491
to pollen, 395
to spores, 395

Sentinel Event Notification System for Occupational Risks (SENSOR), 162, 164

Settled dust samples, for fungal sampling, 525–526

Shingles
after varicella vaccination, 595
in elderly persons, 136

Short-term exposure limit, for toxic substances, 182–183

Silo unloaders disease, 301–302

Sinusitis
allergic fungal, 299
versus occupational rhinitis, 198

Skin
immunization through. *See* Transcutaneous immunization.
infections of, in elderly persons, 58
occupational disorders of. *See* Contact dermatitis.

Skin testing
for cockroach allergy, 495
for egg allergy, 567–569
for latex allergy, 211, 213
in contact dermatitis, 280–281
in occupational asthma, 243

Smallpox vaccine, **729–741**
adverse effects of, 584–585, 733–734
contraindications for, 731–732, 734
controversies over, 737–738
current product for, 730
efficacy of, 732–733
egg allergy and, 643
in eradication program, 729
in HIV infection, 737
postexposure administration of, 732, 736–737
reactogenicity of, 733–734
research on, 738
terrorism threat and, 729–730
United States programs involving, 736–737
vaccination site protection in, 735–736
vaccinia virus transmission by, 735–736

Smell sensation, in toxic exposures, 184–186

Smoking
in elderly persons, cytokines and, 21
occupational asthma and, 160, 228

Soap, skin damage from, contact dermatitis after, 274

Sociogenic theory, of environmental sensitivity, 315

Soils, floristic zones and. *See* Floristic zones.

Solid organ transplantation, vaccinations in, 616–619

Solomon floristic zones, 359–360

Somatic syndromes, versus environmental sensitivity, 317

Southeastern Coastal Plain floristic zone, 367

Soybean dust, occupational asthma from, 240

Specificity, in epidemiology, definition of, 155–156

Spirometry
in occupational asthma, 158–160
in toxic exposure, 180

Spondyloarthropathy, in elderly persons, 76–78

Spore counts
aerobiology of, 392–393
controlled-exposure studies of, 403–404
dose response to, 404–405
geographic variation in, 392
health effects and, 394–400
hospital admissions and, 402–403
interpretation of, 405–406
meteorologic variables in, 416–418
natural-exposure studies of, 401–403
related to human exposure, 393–394
reporting of, 394
sampling methods for, 393–394
spore size and, 392–393

Spore traps, for fungal air sampling, 526

Stachybotrys, occupational exposure to, 302–305

Statins, cytokines and, 30

STEL (short-term exposure limit), for toxic substances, 182–183

Storage mites, habitats of, 445

Stratum corneum, in transcutaneous immunization
penetration of, 785–788
structure of, 784

Streptococcus pneumoniae vaccines
allergy to, 584

components of, 564–565
in HIV infection, 612–613

Stress, in elderly persons, vaccine efficacy and, 50–51

Submicronic bioaerosols, from pollen, 392, 418

Suction sieve-plate samplers, for bioaerosol sampling, 345–347

Suction slit impactors, for bioaerosol sampling, 343–345

Surveillance, for occupational asthma, 161–162

Surveys, for epidemiologic studies, in occupational asthma, 157–158

Swabs, for fungal sampling, 524–525

Sweating, contact dermatitis related to, 274

SWORD program, for occupational asthma surveillance, 164, 221, 223

Systemic lupus erythematosus, in elderly persons, 77–78

T

T lymphocytes
in asthma, 227
in contact dermatitis, 271–272
in elderly persons
apoptosis of, 67–71
autoimmune disease and, 66–71
immune-risk phenotype and, 5–6, 9
infections and, 60
interventions to improve function, 8–9
proliferation of, in Alzheimer's disease, 107–108
replicative senescence of, 49–50, 67
tumor susceptibility and, 94–100
vaccine efficacy and, 46–50

Tape slides, for fungal sampling, 523–524

Temperature
aeroallergen count and, 414–415
floristic zones and. *See* Floristic zones.

Tetanus vaccine
components of, 560
in DTaP vaccine. *See* Diphtheria, tetanus, acellular pertussis vaccine.

Tetracycline, for anthrax, 715

Thermal tolerance, of dust mites, 462–463

Thimerosal, in vaccines
allergy to, 573–576
safety of, 598

Thompson's law, for pollination, 377

Threshold limit values, for toxic substances, 182–183

Thrombocytopenia, vaccinations in, 622–623

Thunderstorms, high aeroallergen counts associated with, 418–419

Thymus, of elderly persons, 70–71, 93–94
hormone replacement for, 139

Thyroid hormone, for environmental sensitivity, 322

TLVs (threshold limit values), for toxic substances, 182–183

Toluene diisocyanate, occupational asthma from, 223, 226–227

Toluene diisocyanate challenge test, in occupational asthma, 263

Toxic exposures, occupational, **177–191**
anatomic considerations in, 184
effects of, 183–189
exposure assessment in, 181–183
history in, 178–180
injury in, 188–189
irritation from, 186–188
laboratory studies in, 180–181
odor perception and, 184–186
patient evaluation in, 178–181
physical examination in, 180
radiography in, 181
response to, versus allergic response, 177
routes for, 177
sensitivity in. *See* Environmental sensitivity.
spirometry in, 181
systemic toxicity in, 189
to fungi, 291–309
types of, 177–178

Toxicity, in fungal exposure, 504–505

Toxoid vaccines, components of, 560

Transcription factors, in elderly persons, tumor susceptibility and, 98–100

Transcutaneous immunization, **783–809**
adjuvants for, 791–792
safety of, 792–795
antigen molecular size for, 785
clinical studies of, 802–805
immune response to, 800–801
mucosal response to, 801–802
optimization of delivery for, 785–791
skin structure and, 784–785
with injected vaccine, 795–800

Transplantation, vaccinations in
hematopoietic stem cell, 613–616
solid organ, 616–619

Travel vaccines
for elderly persons, 44
in immunodeficiency, 625

Trees
in cities. *See* Urban jungle.
pollens of, forecasting of. *See* Pollen counts, forecasting of.

Tricothecenes, toxicity of, 302–305

Trimellitic anhydride, occupational asthma from, 225, 228

Tumor(s), susceptibility to, in elderly persons, **83–103**
aggressiveness and, 88
animal models of, 93–98
at-risk population size and, 84–87
environmental factors in, 87–88
genetic factors in, 87–88
immune factors in, 88–89, 137
immunotherapy effects on, 91–93
T-lymphocyte function and, 94–100
thymic function and, 93–94
transcription factors and, 98–100
tumor-associated macrophages and, 100–101
type of cancer and, 83–84
with immunodeficiency, 89–91

Tumor-associated macrophages, in elderly persons, 100–101

Tumor necrosis factor α, in elderly persons
Alzheimer's disease and, 22–23, 107–109
antioxidants and, 30–31
body composition and, 20
cardiovascular disease and, 24–25
chronic disease and, 22–27
chronic elevations of, 18–22
diabetes mellitus and, 26
exercise and, 29–30
frail, 26–27
hypertension and, 21
in acute-phase response, 17–18
infections and, 20
mortality and, 27–29
polymorphisms in, 21–22
pro-inflammatory effects of, 15–16
statins and, 30

Typhoid vaccines
allergy to, 578
components of, 565

U

Universal allergy. *See* Environmental sensitivity.

Urban jungle, **371–387**
allergy and
availability of allergens in, 372
human behavior in, 372
impact of, 372
landscaping development in, 372–373
people concentration in, 371–372
pollens in
amount causing reactions, 374
avoidance of, 384
exposure to, 382–384
modes of pollination, 376–378
natural plant distribution and, 379
Ogren Plant Allergy Scale for, 384–385
ornamental plants, 381–382
production of, 374–375
regional distribution of, 378–379
unnatural plant distribution and, 379–382
weed, 380–381
pollution reduction in, 385
definition of, 371

Urinary tract infections, in elderly persons, 57–58, 111–112

Urticaria. *See also* Contact urticaria.
from Japanese encephalitis vaccine, 671–672, 674, 677–678
in cockroach allergy, 490–491
in egg allergy
from measles, mumps, rubella immunization, 637–639
from yellow fever immunization, 640–641

V

Vaccine(s). *See also specific microorganisms.*
allergy to, **555–588**
aluminum salts, 578–579
antibiotics, 576–577
bacterial antigens, 579–580
diphtheria, tetanus, acellular pertussis, 581
egg. *See* Egg allergy, vaccine reactions in.
gelatin, 570–573
Haemophilus influenzae, 583
hepatitis B virus, 583
immune mechanisms in, 556–558
infectious agents, 578
influenza, 584
Japanese encephalitis, **663–695**
latex, 577

measles, mumps, rubella, 582
pneumococcal, 584
poliovirus, 583
rabies, 580
smallpox, 584–585
thimerosal, 573–576
varicella, 584
versus nonallergic reactions, 582
yeast, 578
aluminum inclusion macrophagic myofasciitis from, **697–709**
combination, 652–653
components of, 560–565
for elderly persons, **41–55**
amyloid, for Alzheimer's disease, 110–111
efficacy of
barriers to, 46–48
immunosenescence and, 2
organismic aging and, 50–51
for immune system enhancement, 139
mucosal, 45–46
replicative senescence and, 49–50
research and development issues in, 42
response to, 42–45
multiple, **647–662**
antigenic load in, 653–654
background of, 647–648
combination vaccines for, 652–653
epitopic overload in, 654–655
for infants versus adults, 650–652
Gulf War syndrome and, 706
in HIV infection, 656
in immunodeficiency, 656
infections after, 655
misconceptions about, 648
neonatal immune system and, 649
parental concerns about, 648–649
response to, in illness, 655–656

Vaccine Adverse Events Reporting System (VAERS), 589–590, 598–599

Vaccine safety, **589–602**
allergy, **555–588**
anthrax, **711–728**
antigenic overload and, **647–662**
atopy and, 597–598
autoimmunity and, 597–598
diphtheria, tetanus, acellular pertussis, 591–593
Haemophilus influenzae, 594
hepatitis B virus, 591
in egg allergy, **633–646**
in immunodeficiency, **603–631**, 656
influenza virus, 590–591
live attenuated cold-adapted, **743–764**
Japanese encephalitis, 563, 578, **663–695**
Lyme disease, 596–597
measles, mumps, rubella, 595–596
meningococcal, **765–782**
overview of, 589–590
poliovirus, 593–594
programs for, 598–599
rotavirus, 594–595
smallpox, 643, **729–741**
thimerosal, 598
transcutaneous, **783–809**
varicella, 595

Vaccinia virus, for smallpox vaccine. *See also* Smallpox vaccine.
transmission of, 735–736

Vapor(s), toxic, exposure to, 178

Vapor challenge test, in occupational asthma, 263

Varicella-zoster virus
infections with, immune system effects of, in elderly persons, 136
vaccines for
allergy to, 584
components of, 561
in elderly persons, 43
in immunodeficiency, 625
safety of, 595

Variola vaccine. *See* Smallpox vaccine.

Vegetation, in cities. *See* Urban jungle.

Viruses, environmental sensitivity from, 316

Vitamin(s)
for environmental sensitivity, 321–322
supplementation of, in elderly persons, 140–141

Vitamin E, for elderly persons, 8, 140–141

Vitiligo, occupational, 281

Vocal cord dysfunction, versus asthma, 172–173

W

Water, skin damage from, contact dermatitis after, 274

Water balance, of dust mites, 459–462

Weather. *See* Meteorologic variables.

Weed pollen, in cities, 380–381

Weight loss, in Alzheimer's disease, 112

Western red cedar, occupational asthma from, 228

Wind
pollen dispersal in, 376–378
speed and direction of, aeroallergen count and, 415–416

Wipes, for fungal sampling, 524–525

Workplace
disorders related to. *See* Occupational disorders.
dust mite allergens in, 451

Y

Yeasts, environmental sensitivity from, 316, 321

Yellow fever vaccine
allergy to, 566
components of, 561
egg allergy and, 639–642

Z

Zinc supplementation, in elderly persons, 140–141